公开(公告)号：EP2227237A1

公开(公告)日：2010-09-15

申请号：EP08853658.6

申请日：2008-11-27

申请人： Hadasit Medical Research Services & Development Ltd. ,  Ben-gurion University Of The Negev Research And Development Authority

发明人： ILAN, Yaron ,  LALAZAR, Gadi ,  SHTEYER, Eyal ,  BEN-YAAKOV, Ami ,  COHEN, Smadar ,  ELKAYAM, Tsiona

IPC分类号： A61K31/734 ,  A61K31/738 ,  A61L27/20 ,  A61L31/04 ,  A61P1/16

CPC分类号： A61K31/738 ,  A61K31/734 ,  A61L27/20 ,  A61L31/042 ,  A61P1/16 ,  C08L5/04

摘要： The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.

摘要翻译： 本发明涉及在有需要的受试者中治疗肝脏疾病的方法。 更具体地，本发明的方法基于治疗有效量的至少一种生物相容性藻酸盐生物材料，其任何修饰以及它们的任何组合，优选全身施用。 本发明还提供了在患有肝脏疾病的受试者中维持血清白蛋白水平和/或降低血清AST和ALT的方法。 此外，本发明提供了使用本发明描述的藻酸盐生物材料减少患有肝脏疾病的受试者的损伤的肝组织中细胞凋亡和诱导细胞增殖的方法。

公开(公告)号：EP2227237B1

公开(公告)日：2017-11-15

申请号：EP08853658.6

申请日：2008-11-27

申请人： Hadasit Medical Research Services & Development Ltd. ,  Ben-gurion University Of The Negev Research And Development Authority

发明人： ILAN, Yaron ,  LALAZAR, Gadi ,  SHTEYER, Eyal ,  BEN-YAAKOV, Ami ,  COHEN, Smadar ,  ELKAYAM, Tsiona

IPC分类号： A61K31/734 ,  A61K31/738 ,  A61L27/20 ,  A61L31/04 ,  A61P1/16

CPC分类号： A61K31/738 ,  A61K31/734 ,  A61L27/20 ,  A61L31/042 ,  A61P1/16 ,  C08L5/04

摘要： The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.